ALK CEO after upgrade: "In spite of Covid-19, ALK is on a roll – I'm really proud"
A broad effort across the organization and high tablet sales cause ALK to raise its guidance for its 2020 earnings. However, postponed costs and reduced travel activity contribute to the upgrade, which might have been even larger had it not been for Covid-19, says CEO.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY NIELSINE NIELSEN
Things are going so well for the allergy company ALK that the firm told the market Thursday morning that it was raising its full-year earnings guidance.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK launches tablet vaccine for tree pollen allergy
For subscribers
